2021-11-182021-11-182006Özkan, A. vd. (2006). ''Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy''. Neuroradiology, 48(12), 887-892.0028-39401432-1920https://doi.org/10.1007/s00234-006-0142-8https://link.springer.com/article/10.1007/s00234-006-0142-8http://hdl.handle.net/11452/22706Introduction Reversible posterior leukoencephalopathy syndrome (RPLS) is a recently described clinical and radiological entity comprising headache, seizures, altered level of consciousness and visual disturbances in association with transient posterior cerebral white-matter abnormalities. Method We report a young woman with Burkitt's lymphoma who developed RPLS after combined chemotherapy administered during the tumor lysis syndrome. Results The symptoms in this patient fitted well with those of RPLS; they included abrupt alterations in mental status, seizures, headache, visual changes and characteristic neuroradiological findings. She was given further combination chemotherapy without any neurological complications, at which time she had already recovered from both RPLS and tumor lysis syndrome. Conclusion Although many etiological factors have been reported in the development of RPLS, the underlying mechanism is not yet well understood. With prompt and appropriate management, RPLS is usually reversible, and chemotherapy can be continued after complete recovery from RPLS. We suggest that tumor lysis syndrome should be considered as a contributory factor to the development of RPLS in patients for whom treatment with combined chemotherapy for hematological malignancies is planned.eninfo:eu-repo/semantics/closedAccessNeurosciences & neurologyRadiology, nuclear medicine & medical imagingTumor lysis syndromeReversible posterior leukoencephalopathy syndromeMRIChemotherapyLeukemiaLymphomaVasospasmPatientCombination chemotherapyEncephalopathy syndromeTumor lysis syndromeSyndromeSeizuresMagnetic resonance imagingHypertensive encephalopathyHumansHeadacheFemaleFatal outcomeComaBurkitt lymphomaBlindness, corticalAntineoplastic combined chemotherapy protocolsArticle0002423655000042-s2.0-33751536932887892481216983525Clinical neurologyNeuroimagingRadiology, nuclear medicine & medical imagingPosterior Reversible Encephalopathy Syndrome; Eclampsia; Hypertension EncephalopathyVincristinePhenytoinMethotrexateDoxorubicinDexamethasoneCytarabineCyclophosphamideCorticosteroidAllopurinolWeight reductionVomitingTumor lysis syndromeTonic clonic seizureRisk factorReversible posterior leukoencephalopathy syndromeRehydrationPriority journalPathogenesisNausea; nuclear magnetic resonance imagingLeukoencephalopathyHumanHospital admissionHeadacheGrand mal seizureFollow upFemaleComputer assisted tomographyComaCase reportCancer combination chemotherapyBurkitt iymphomaBlurred visionArticleAdultAbdominal pain